Lee Xiaolong, Gao Ming, Ji Yifeng, Yu Yang, Feng Ying, Li Yigong, Zhang Yan, Cheng Wenyuan, Zhao Wenchuan
Department of Thyroid & Neck, Tianjin Medical University Cancer Hospital, Tianjin, China.
Ann Surg Oncol. 2009 Feb;16(2):240-5. doi: 10.1245/s10434-008-0233-3. Epub 2008 Nov 26.
Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAF(V600E) mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAF(V600E) mutational status of them was identified. BRAF(V600E) mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAF(V600E) mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAF(V600E) mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAF(V600E) mutation may be a marker of high aggressiveness in PTMCs.
甲状腺乳头状癌常以微小癌的形式出现。一些甲状腺乳头状微小癌（PTMC）根据疾病晚期、甲状腺外侵犯和严重的颈部淋巴结转移情况，被认为具有高侵袭性。尽管有几个因素被认为可预测PTMC发生侵袭性，但侵袭性的起源却鲜有研究。为回答这个问题，研究了BRAF（V600E）突变与高侵袭性PTMC之间的相关性。调查了总共64例PTMC的临床病理特征，并确定了它们的BRAF（V600E）突变状态。仅在PTMC中检测到BRAF（V600E）突变（37.5%）。数据显示BRAF（V600E）突变的发生与临床病理参数，如性别、年龄和肿瘤样病变组合之间无相关性。具有高侵袭性（疾病晚期、甲状腺外侵犯和淋巴结转移）的PTMC中BRAF（V600E）突变的发生率显著高于（p<0.05）无侵袭性行为的PTMC。BRAF（V600E）突变的PTMC比未发生突变的PTMC表现出更高的侵袭性迹象。BRAF（V600E）突变可能是PTMC高侵袭性的一个标志物。
